Abstract Details

Title The Phenotypic Differences between Probable Migraine and Definite Migraine

Topic Headache

Presentation(s) P03 - (-)

Poster/Presentation
Number 107

Objective

Background BACKGROUND: Many headache sufferers do not meet the ICHD-II criteria for DM. Therefore, individuals who meet all but one of the criterion are categorized as having PM and they tend to remain undiagnosed and untreated. Also, the frequency of PM remains elusive; some of the published literature estimate PM to be at least as prevalent as DM while others report PM to affect about 5% of the population or less.

Design/Methods DESIGN/METHODS: We conducted a cross sectional survey of high school students using a validated questionnaire which covered the diagnostic features of DM and PM as specified by the ICHD-II. The survey also inquired about subjects' headache frequency and treatment history. Headache related disability was ascertained using Headache Impact Test 6 (HIT-6).

Results RESULTS: The participants included 309 girls and 77 boys with a mean age of 16.5 years. The prevalence of DM and PM in our cohort were 16% and 26% respectively. Overall, headaches were more frequent in the DM group although this did not reach statistical significance (chi-square p<0.06). There was no statistical significance between DM and PM in respect to seeking medical care (chi-square p<0.23). Those with DM were more likely to be diagnosed as migraineurs by pediatricians (chi-square p<0.001). Moreover, individuals in the DM group reported higher frequencies of analgesic use (chi-square p<0.001). The individuals with DM experienced higher degrees of headache related disability as measured by HIT-6 (ANOVA p<0.0001).

Conclusions CONCLUSIONS: We propose that PM carries a milder phenotype than DM indicated by lower HIT-6 scores and rates of analgesic use. Also PM appears to be at least as prevalent of DM and its accurate recognition, diagnosis and treatment are paramount to improve patients' quality of life.

Authors/Disclosures
Mitra Assadi Khansare, MD, FAAN (Christiana Care) PRESENTER	No disclosure on file
	No disclosure on file
Yadira Velazquez-Rodriguez, MD	No disclosure on file
Derrick Robertson, MD	Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Greenwich Biosciences. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mallinckrodt. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PRIME CME. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for McVeigh. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Mccumber. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Goodis. The institution of Dr. Robertson has received research support from Biogen. The institution of Dr. Robertson has received research support from EMD Serono. The institution of Dr. Robertson has received research support from Jansenn. The institution of Dr. Robertson has received research support from Genentech. The institution of Dr. Robertson has received research support from Patient-Centered Outcomes Research Institute. The institution of Dr. Robertson has received research support from Novartis. The institution of Dr. Robertson has received research support from Sanofi Genzyme. The institution of Dr. Robertson has received research support from TG Therapeutics. The institution of Dr. Robertson has received research support from Prime. The institution of Dr. Robertson has received research support from Greenwich Biosciences. The institution of Dr. Robertson has received research support from Atara Biotherapeutics. The institution of Dr. Robertson has received research support from CorEvitas. The institution of Dr. Robertson has received research support from Anokion. The institution of Dr. Robertson has received research support from UCB Biosciences. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Consortium of Multiple Sclerosis Centers. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Multiple Sclerosis Association of America.
	No disclosure on file

��ɫ��

��ɫ��